Cell-Based Anticancer Assay Testing

This contract involves the performance of standardized in vitro cell-based assays to assess the efficacy and toxicity of small-molecule drug candidates targeting cancer cell lines. The work includes dose-response profiling and determining the half-maximal inhibitory concentration (IC50) to evaluate how these compounds affect cancer cells. The objective is to generate reliable data on the potential therapeutic value and safety of these drug candidates in preclinical testing. The subcontract is managed under the National Institutes of Health, part of the Department of Health and Human Services, with the place of performance specified as Bethesda, zip code 20892. The solicitation was posted on May 29, 2026, with a response deadline of June 8, 2026. The NAICS code 541380 indicates professional scientific and technical services. The contract emphasizes timely and accurate execution of assays critical for advancing cancer drug development programs.